Telomir details new Telomir-1 preclinical cellular data

Telomir Pharmaceuticals, Inc. reported new preclinical cellular data on its lead investigational compound Telomir-1, studied as Telomir-Zn.

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported new preclinical cellular data on its lead investigational compound Telomir-1, studied as Telomir-Zn. In collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to rapidly and dose-dependently increase intracellular zinc and reduce labile ferrous iron within about 30 minutes, with effects sustained for two hours and without loss of cell viability.

The coordinated metal redistribution suggests a potential mechanism that may lower oxidative stress and support genomic and epigenetic stability, processes implicated in both cancer and aging. The company is advancing additional preclinical programs in triple-negative breast cancer and longevity models and currently plans to submit an Investigational New Drug application in the first quarter of 2026.

Insights

Biotech and drug development analyst

Telomir shares mechanistic preclinical data and targets an IND filing in early 2026.

The company highlights preclinical cellular results for Telomir-1 (Telomir-Zn) showing rapid, dose-dependent increases in intracellular zinc and reductions in labile ferrous iron over a two-hour window without harming cell viability. This supports an epigenetic and oxidative stress–related mechanism relevant to cancer and aging biology.

The described zinc–iron modulation ties into known roles of iron in reactive oxygen species generation and zinc in DNA repair and chromatin structure. While encouraging mechanistic support, these data are preclinical and non-clinical efficacy or safety in humans is not addressed here.

Telomir notes ongoing and completed preclinical programs, including work in triple-negative breast cancer and longevity-focused models, and states that it is finalizing IND-enabling activities with a planned Investigational New Drug submission in the first quarter of 2026. Future regulatory and clinical milestones will depend on outcomes not detailed in this disclosure.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Telomir Pharmaceuticals (TELO) report in its latest 8-K filing?

Telomir Pharmaceuticals reported new preclinical cellular data for its lead compound Telomir-1, in the Telomir-Zn form. The findings describe coordinated zinc–iron modulation linked to oxidative stress and epigenetic stability, and the company reaffirmed plans to file an Investigational New Drug application in the first quarter of 2026.

What are the key preclinical findings for Telomir-1 (Telomir-Zn) reported by TELO?

In cellular studies, Telomir-Zn induced rapid, dose-dependent increases in intracellular zinc and reductions in labile ferrous iron within about 30 minutes, sustained for two hours. These changes occurred without loss of cell confluence or viability, suggesting a coordinated metal-redistribution process rather than nonspecific or cytotoxic effects.

How do Telomir Pharmaceuticals’ new data relate to cancer and aging mechanisms?

The company links the observed zinc–iron redistribution to reduced oxidative stress and more stable epigenetic and mitochondrial function. Dysregulated metal balance, oxidative stress, and epigenetic instability are described as shared upstream drivers of cancer biology and age-related cellular decline, positioning Telomir-1’s mechanism at a foundational biological level.

What future regulatory plans did Telomir Pharmaceuticals (TELO) outline for Telomir-1?

Telomir Pharmaceuticals stated it is finalizing IND-enabling activities for Telomir-1 and currently plans to submit an Investigational New Drug application in the first quarter of 2026. This planned submission would be a key step toward initiating human clinical trials, subject to regulatory review and acceptance.

What additional preclinical programs is Telomir Pharmaceuticals currently advancing?

The company reported a portfolio of ongoing and completed preclinical research programs, including studies in triple-negative breast cancer models and longevity-focused models. Based on data from completed work, manuscript submissions to peer-reviewed journals have been initiated, while further data generation continues from ongoing preclinical studies.

Who collaborated with Telomir Pharmaceuticals on the Telomir-Zn cellular studies?

The preclinical cellular studies evaluating Telomir-1 in the form of Telomir-Zn were conducted in collaboration with Smart Assays Biotechnologies. This partnership supported detailed assessment of intracellular metal redistribution, including increased zinc levels and reduced labile ferrous iron, under controlled, dose-dependent experimental conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 07:30 AM Learn about SEC filing dates

false 0001971532 0001971532 2026-02-05 2026-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 – Other Events

Telomir Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity—without relying on cytotoxic mechanisms.

On February 5, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) reported new findings from preclinical cellular studies evaluating its lead investigational compound, Telomir-1, in the form of Telomir-Zn.

In these studies, done in collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to induce a rapid and coordinated intracellular redistribution of metals, characterized by increased intracellular zinc levels and a reciprocal reduction in labile ferrous iron. The effects were dose-dependent, detected within approximately 30 minutes of exposure, sustained over a two-hour period, and observed without loss of cell confluence or viability in the evaluated cellular models. Zinc accumulation and iron reduction occurred over similar concentration ranges and timeframes, supporting a coordinated intracellular process rather than independent or nonspecific metal effects.

Iron and zinc play fundamentally different roles in cellular biology. Excess labile iron is redox-active and can drive reactive oxygen species generation, contributing to mitochondrial damage, DNA instability, and dysregulation of metal-dependent epigenetic enzymes. Zinc, by contrast, is redox-inert and supports chromatin structure, DNA repair, antioxidant defenses, and proper regulation of epigenetic processes. The observed simultaneous reduction of redox-active iron and enrichment of intracellular zinc suggests a metal-exchange process that may reduce oxidative stress while stabilizing epigenetic and mitochondrial function.

These findings are significant because dysregulated metal balance, oxidative stress, and epigenetic instability are shared upstream drivers of both cancer biology and age-related cellular decline. By demonstrating coordinated zinc–iron modulation, the reported data support a mechanism that acts at a foundational biological level rather than targeting downstream disease manifestations.

The Company also reported that it continues to advance a portfolio of ongoing and completed preclinical research programs, including studies in triple-negative breast cancer models and longevity-focused models. Based on data generated from completed studies, manuscript submissions to peer-reviewed journals have been initiated, while additional data continue to be generated from ongoing preclinical studies.

In addition, the Company reported that it is finalizing IND-enabling activities and currently plans to submit an Investigational New Drug application in the first quarter of 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: February 5, 2026	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer